Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Roche : faces UK pricing row over multiple sclerosis drug Ocrevus

share with twitter share with LinkedIn share with facebook
share via e-mail
09/10/2018 | 01:14am CEST
Logo of Swiss drugmaker Roche is seen at its headquarters in Basel

LONDON (Reuters) - Roche faces a fresh row over drug pricing in Britain, following a decision by the body responsible for medicine use within the state health service not to approve its drug Ocrevus for treating a highly disabling form of multiple sclerosis (MS).

In June, the National Institute for Health and Care Excellence (NICE) endorsed Ocrevus for relapsing-remitting MS - the most common type of the disease - but it has now rejected it for the rarer and more severe primary-progressive form of MS.

Ocrevus is the only available treatment for primary-progressive MS (PPMS), while there are several drugs for relapsing-remitting MS (RRMS), and Roche UK general manager Richard Erwin said Monday's decision was "devastating news" for patients.

It is not the first time the Swiss drugmaker has clashed with NICE, which determines if drugs are cost-effective enough to be used in the National Health Service (NHS) in England and Wales.

Roche has also battled to get a number of its cancer drugs approved by NICE in the past, prompting Chief Executive Severin Schwan to brand Britain's health system as "stupid" three years ago https://uk.reuters.com/article/us-roche-cancer-britain/roche-ceo-attacks-britains-stupid-cancer-drug-system-idUKKCN0R81J620150908.

In the case of Ocrevus, Roche said it had reached a stalemate because the authorities were not allowed to even consider a confidential discounted price for using the drug in PPMS that was different from the RRMS price.

That is a problem because the evidence showing the benefit of Ocrevus in PPMS is not as compelling as in RRMS, so a lower price would be needed to reach NICE cost-effectiveness thresholds.

The restriction meant NICE had to consider the existing RRMS approved price for the PPMS indication and this was deemed too expensive. In a statement, NICE said the size and duration of the drug's benefits in PPMS were uncertain and it could not be considered an acceptable use of NHS resources.

Worldwide, Ocrevus has proved to be a big commercial success for Roche, with sales topping $1 billion in the first half of 2018, and the company said it hoped an agreement could be reached for its use within the NHS.

"Roche is confident that given the flexibility to offer an indication-specific price, we will be able to offer a price that is deemed cost-effective for PPMS," the company said.

(Reporting by Ben Hirschler; Editing by Mark Potter)

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ROCHE HOLDING LTD.
09/25GENENTECH : ’s TECENTRIQ in Combination with Chemotherapy Helped People Li..
09/25NOVARTIS : Cuts Over 2,000 Jobs in Switzerland as It Continues to Refocus -- Upd..
09/24GENENTECH : ’s TECENTRIQ in Combination With Pemetrexed and Platinum-Based..
09/24GENENTECH : ’s Investigational Medicine Entrectinib Showed a Durable Respo..
09/21AbbVie Gets Positive CHMP Opinion for Combination of Venclyxto With Rituximab..
09/13Roche Works to Fill Sales Gap as Biosimilars Emerge -Reuters
09/13Roche steps up efficiency drive to take sting out of biosimilars
09/13ROCHE : FDA Approves Subcutaneous Formulation of Actemra for Use in Active Syste..
09/13ROCHE : boss says Brexit and curbs on drug use pose threat to UK science
09/10U.K. Health Regulator Rejects Roche's MS Drug
More news
News from SeekingAlpha
09/25Pfizer facing difficult path to ramp up biosimilar business 
09/25ARVINAS IPO : 40% Is Cash, But Research Is At An Early Stage 
09/25Dexcom Investors Are Whistling Past The Graveyard 
09/24Express Scripts taking credit for Gilead's planned launch of generic HCV meds 
09/24Roche's Tecentriq + chemo improved progression-free survival in late-stage st.. 
Financials (CHF)
Sales 2018 56 402 M
EBIT 2018 19 128 M
Net income 2018 12 934 M
Debt 2018 4 714 M
Yield 2018 3,72%
P/E ratio 2018 15,62
P/E ratio 2019 15,32
EV / Sales 2018 3,70x
EV / Sales 2019 3,54x
Capitalization 204 B
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 259  CHF
Spread / Average Target 9,8%
EPS Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-4.20%211 344
JOHNSON & JOHNSON2.26%376 847
PFIZER20.90%257 522
NOVARTIS-0.63%217 697
MERCK AND COMPANY25.79%188 241
AMGEN17.94%134 121